A Medical Approach to the Monoamine Oxidase Inhibition by Using 7Hbenzo[ e]perimidin-7-one Derivatives

Bacho, Mitchell; Coelho-Cerqueira, Eduardo; Follmer, Cristian; Nabavi, Seyed Mohammad; Rastrelli, Luca; Uriarte, Eugenio; Sobarzo‐Sánchez, Eduardo

doi:10.2174/1568026616666160824120929

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aminothiazoles derivatives as SUMOylation activators [124] AMN082 [115] Amodiaquine [125,126] Antagonist of the A(2A) adenosine receptor-derivative 49 [127] Apigenin [128][129][130][131] Apomorphine [132,133] l-Arginine [134] Aromadendrin [128] Ascorbic acid [135,136] ASI-1 [12] ASI-5 [12] Astilbin [137] Azilsartan [138] Baicalein [139][140][141] Benserazide [142,143] 7H-Benzo, perimidin-7-one derivatives (R6 = OH) [144] 4H-1-Benzopyran-4-one [145] 8-Benzyl-tetrahydropyrazino, purinedione derivatives (derivative n.57) [146] Bikaverin [147]…”

Section: Compound Name(s) Referencesmentioning

confidence: 99%

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

Tosato

Marco

2019

Biomolecules

View full text Add to dashboard Cite

The present review reports a list of approximately 800 compounds which have been used, tested or proposed for Parkinson’s disease (PD) therapy in the year range 2014–2019 (April): name(s), chemical structure and references are given. Among these compounds, approximately 250 have possible or established metal-chelating properties towards Cu(II), Cu(I), Fe(III), Fe(II), Mn(II), and Zn(II), which are considered to be involved in metal dyshomeostasis during PD. Speciation information regarding the complexes formed by these ions and the 250 compounds has been collected or, if not experimentally available, has been estimated from similar molecules. Stoichiometries and stability constants of the complexes have been reported; values of the cologarithm of the concentration of free metal ion at equilibrium (pM), and of the dissociation constant Kd (both computed at pH = 7.4 and at total metal and ligand concentrations of 10–6 and 10–5 mol/L, respectively), charge and stoichiometry of the most abundant metal–ligand complexes existing at physiological conditions, have been obtained. A rigorous definition of the reported amounts is given, the possible usefulness of this data is described, and the need to characterize the metal–ligand speciation of PD drugs is underlined.

show abstract

Section: Compound Name(s) Referencesmentioning

confidence: 99%

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

Tosato

Marco

2019

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Along with the aging problem of human society, Alzheimer’s disease (AD) has become one of the biggest threats to the modernize population. Alzheimer’s disease is indicated by nerve cells die in the cerebral cortex and accounts for 60 to 80 percent of dementia cases which affected more than 25 million people worldwide in 2000 and may eventually to increase to 114 million by 2050 [6,7,8,9]. General treatment of this disease is the utilization of dopaminergic agonists.…”

Section: Introductionmentioning

confidence: 99%

Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders

et al. 2019

Self Cite

View full text Add to dashboard Cite

Monoamine oxidase inhibitions are considered as important targets for the treatment of depression, anxiety, and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. This has encouraged many medicinal chemistry research groups for the development of most promising selective monoamine oxidase (MAO) inhibitors. A large number of plant isolates also reported for significant MAO inhibition potential in recent years. Differently substituted flavonoids have been prepared and investigated as MAO-A and MAO-B inhibitors. Flavonoid scaffold showed notable antidepressant and neuroprotective properties as revealed by various and established preclinical trials. The current review made an attempt to summarizing and critically evaluating the new findings on the quercetin and related flavonoid derivatives functions as potent MAO isoform inhibitors.

show abstract

Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?

Guglielmi

Carradori

Ammazzalorso

et al. 2019

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

A Medical Approach to the Monoamine Oxidase Inhibition by Using 7Hbenzo[ e]perimidin-7-one Derivatives

Abstract: These results have important implications for the drug design of molecules targeting depression and movement-related disorders.

Cited by 4 publications

References 0 publications

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders

Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?

Contact Info

Product

Resources

About